Oncology
Forschungsbereich der Onkologie
Molekulare Mechanismen von Krebserkrankungen zu entdecken und passende Wirkstoffe zu identifizieren stellen wichtige Teilbereiche in der Krebsforschung dar.
Die Tumordiversität ist sehr hoch. Dementsprechend gehört die Krebsforschung zu einem der vielfältigsten Forschungsbereiche und umfasst viele wissenschaftliche Ansätze.
Wir bieten Ihnen deshalb eine konkurrenzlose Produktvielfalt für die onkologische Forschung und Entwicklung im akademischen sowie pharmazeutischen Bereich an.
Klicke auf die Organe und erfahre mehr über verschiedene Krebsarten
Allgemeine Informationen
Onkologen befassen sich mit der Diagnose, Therapie und Nachsorge von Krebs.
Krebs ist eine Klasse von Krankheiten, bei der sich entartete Zellen unkontrolliert teilen und in andere Gewebe eindringen können. Krebszellen können sich über das Blut- und Lymphsystem auf andere Teile des Körpers ausbreiten. Normalerweise wird die Zellproliferation durch viele Mechanismen streng kontrolliert. Darüber hinaus ist das Immunsystem in der Lage, Krebszellen zu erkennen und zu zerstören.
Funktionieren diese Mechanismen nicht richtig oder das Immunsystem kann die Zellen nicht effektiv zerstören, kann es zu einem malignen Tumor kommen. Eine bösartige Neoplasie ist theoretisch überall möglich, es gibt jedoch Krebsarten, die häufiger vorkommen als andere. Bei Männern ist die Prostata und bei Frauen die Brustdrüse die häufigste Tumorlokalisation.
Relevante Produkte für die onkologische Forschung
| Name | Preis | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Monoclonal Antibody to Interleukin 6 Receptor (IL6R) | Anmelden | Monoclonal Antibody to Interleukin 6 Receptor (IL6R) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) | Anmelden | Monoclonal Antibody to Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Platelet Derived Growth Factor Receptor Beta (PDGFRb) | Anmelden | Monoclonal Antibody to Platelet Derived Growth Factor Receptor Beta (PDGFRb) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Interleukin 24 (IL24) | Anmelden | Monoclonal Antibody to Interleukin 24 (IL24) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to A Disintegrin And Metalloprotease 9 (ADAM9) | Anmelden | Monoclonal Antibody to A Disintegrin And Metalloprotease 9 (ADAM9) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Caspase 4 (CASP4) | Anmelden | Monoclonal Antibody to Caspase 4 (CASP4) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to VEGF Co Regulated Chemokine 1 (VCC1) | Anmelden | Monoclonal Antibody to VEGF Co Regulated Chemokine 1 (VCC1) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to S100 Calcium Binding Protein A8 (S100A8) | Anmelden | Monoclonal Antibody to S100 Calcium Binding Protein A8 (S100A8) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Chemokine (C-X-C Motif) Ligand 14 (CXCL14) | Anmelden | Monoclonal Antibody to Chemokine (C-X-C Motif) Ligand 14 (CXCL14) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Glucocorticoid Receptor (GR) | Anmelden | Monoclonal Antibody to Glucocorticoid Receptor (GR) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to SMAD family member 3 (SMAD3) | Anmelden | Monoclonal Antibody to SMAD family member 3 (SMAD3) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Angiotensin II Receptor 1 (AGTR1) | Anmelden | Monoclonal Antibody to Angiotensin II Receptor 1 (AGTR1) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Insulin Like Growth Factor 1 Receptor (IGF1R) | Anmelden | Monoclonal Antibody to Insulin Like Growth Factor 1 Receptor (IGF1R) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Glucocorticoid Induced Tumor Necrosis Factor Receptor (GITR) | Anmelden | Monoclonal Antibody to Glucocorticoid Induced Tumor Necrosis Factor Receptor (GITR) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Protein Kinase, AMP Activated Beta 1 (PRKAb1) | Anmelden | Monoclonal Antibody to Protein Kinase, AMP Activated Beta 1 (PRKAb1) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Insulin Like Growth Factor Binding Protein 7 (IGFBP7) | Anmelden | Monoclonal Antibody to Insulin Like Growth Factor Binding Protein 7 (IGFBP7) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Suppressors Of Cytokine Signaling 3 (SOCS3) | Anmelden | Monoclonal Antibody to Suppressors Of Cytokine Signaling 3 (SOCS3) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Kallikrein 7 (KLK7) | Anmelden | Monoclonal Antibody to Kallikrein 7 (KLK7) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Formyl Peptide Receptor 2 (FPR2) | Anmelden | Monoclonal Antibody to Formyl Peptide Receptor 2 (FPR2) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Bruton'S Tyrosine Kinase (Btk) | Anmelden | Monoclonal Antibody to Bruton'S Tyrosine Kinase (Btk) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Angiopoietin Like Protein 2 (ANGPTL2) | Anmelden | Monoclonal Antibody to Angiopoietin Like Protein 2 (ANGPTL2) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Mothers Against Decapentaplegic Homolog 4 (Smad4) | Anmelden | Monoclonal Antibody to Mothers Against Decapentaplegic Homolog 4 (Smad4) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Protein Kinase B Beta (PKBb) | Anmelden | Monoclonal Antibody to Protein Kinase B Beta (PKBb) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Signal Transducer And Activator Of Transcription 6 (STAT6) | Anmelden | Monoclonal Antibody to Signal Transducer And Activator Of Transcription 6 (STAT6) | ||||||||||||||||
|
||||||||||||||||||
| Monoclonal Antibody to Tumor Necrosis Factor Ligand Superfamily, Member 13 (TNFSF13) | Anmelden | Monoclonal Antibody to Tumor Necrosis Factor Ligand Superfamily, Member 13 (TNFSF13) | ||||||||||||||||
|
||||||||||||||||||


